MYH3

Across TCGA pan-cancer cohorts, MYH3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYH3 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYH3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYH3 expression acts as an unfavorable survival marker.

HNSC and LSCC are the cancer types where MYH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	II,III,IV	0.733	0.901	.032	6	view →
LSCC	DFS	Median	All	0.746	0.950	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYH3–HNSC (OS)

Open the HNSC breakdown →